ANG1005
- Generic Name
- ANG1005
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Associated Conditions
- -
- Associated Therapies
- -
Overcoming Barriers in Glioblastoma—Advances in Drug Delivery and Resistance
Efflux pump inhibitors aim to overcome multidrug resistance, with third-generation inhibitors like elacridar showing promise despite toxicity concerns. Nanoparticles improve drug delivery to the brain, with liposome-based NPs being common. Despite advancements, challenges like protein corona formation and administration methods affect efficacy. Optimizing nanoparticle features is crucial for effective brain tumor treatments.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath